65422-72-2

Usage

Uses

Used in Pharmaceutical Industry:
2-OXO-2,3-DIHYDRO-BENZOOXAZOLE-5-CARBOXYLIC ACID is used as a pharmaceutical compound for its potential therapeutic activities. Its anti-inflammatory, antimicrobial, and anticancer properties make it a valuable compound for the development of new drugs and treatments.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-OXO-2,3-DIHYDRO-BENZOOXAZOLE-5-CARBOXYLIC ACID serves as a versatile building block for the synthesis of novel drug candidates. Its molecular structure and functional groups allow for the creation of new compounds with potential therapeutic applications.
Used in Organic Synthesis:
2-OXO-2,3-DIHYDRO-BENZOOXAZOLE-5-CARBOXYLIC ACID is utilized in organic synthesis due to its chemical reactivity and the presence of functional groups. This allows for the formation of various derivatives and the development of new chemical entities with potential applications in different industries.

Upstream product

• 65422-70-0 methyl 2-oxo-2,3-dihydro-1,3-benzoxazole-5-carboxylate 
• 57-13-6 urea 
• 536-25-4 methyl 3-amino-4-hydroxybenzoate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 79-22-1 methyl chloroformate 

Downstream Products

• 154780-52-6 3-methyl-2-oxo-2,3-dihydro-benzooxazole-5-carboxylic acid 
• 154780-55-9 3-methyl-2-oxo-2,3-dihydro-benzooxazole-5-carbonyl chloride 
• 1221408-42-9 Y-QA₁₄ 

Relevant academic research and scientific papers

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

Compound with dopamine D3 receptor adjusting activity, and applications thereof

The invention relates to a compound with dopamine D3 receptor adjusting activity, and applications thereof, and more specifically discloses dopamine receptor D3R as a novel target of post-traumatic stress disorder (PTSD) in prevention, treatment/or auxiliary treatment of PTSD, and screening of anti-PTSD medicines, and relates to applications of a compound with dopamine receptor D3R adjusting activity in preparation of medicines used for preventing, treatment and/or auxiliary treatment of PTSD.

NOVEL DOPAMINE D3 RECEPTOR LIGANDS, THE PREPARATION AND USE THEREOF

The invention discloses novel piperazine derivatives represented by formula I having activity for modulating dopamine D3 receptor, their stereoisomers, pharmaceutical salts, solvates, and the pharmaceutical compositions containing such compounds, their preparation and the use of such compounds for preventing or treating the diseases correlated with central nervous system disorder, such as Parkinson's disease, schizophrenia, drug addiction and relapse and the like, as well as the use of such compounds for kidney protection and immune modulation, or as implemental medicine for researching the function of D3R and the diseases correlated with disorder of D3R function.

NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME

The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson''s disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.

Neutrophil inhibitors to reduce inflammatory response

The invention provides novel compounds selected from the group consisting of: The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.